A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out

Vivos Inc.
(OTCQB: RDGL)

Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)
Home
Press Releases
RadioGel®
IsoPet®
PRnT™
IDE Submission
Subscribe
The History of Vivos Inc.
The Peltier Chiller
Quarterly Reports
SEC Filings
Research Papers
Meet The Team
FAQ's
Contact Us

Vivos Inc.
(OTCQB: RDGL)

Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)Vivos Inc. (OTCQB: RDGL)
Home
Press Releases
RadioGel®
IsoPet®
PRnT™
IDE Submission
Subscribe
The History of Vivos Inc.
The Peltier Chiller
Quarterly Reports
SEC Filings
Research Papers
Meet The Team
FAQ's
Contact Us
More
  • Home
  • Press Releases
  • RadioGel®
  • IsoPet®
  • PRnT™
  • IDE Submission
  • Subscribe
  • The History of Vivos Inc.
  • The Peltier Chiller
  • Quarterly Reports
  • SEC Filings
  • Research Papers
  • Meet The Team
  • FAQ's
  • Contact Us

  • Home
  • Press Releases
  • RadioGel®
  • IsoPet®
  • PRnT™
  • IDE Submission
  • Subscribe
  • The History of Vivos Inc.
  • The Peltier Chiller
  • Quarterly Reports
  • SEC Filings
  • Research Papers
  • Meet The Team
  • FAQ's
  • Contact Us

RAdioGel®.

Our New Generation Cancer Treatment

Our RadioGel® division assembled a team of talented and dedicated professionals who are passionate about improving cancer treatment through cutting edge technology and an advance knowledge for innovative solutions to cancer therapy. Our team includes brilliant scientists, dedicated researchers, innovative engineers, and top notch business professionals, all of whom bring unique skills and perspectives to our work. 


RadioGel® is currently not approved for human use. 

The Road To IDE Submission

Read More

Vivos Inc.

Vivos Inc. (OTCQB: RDGL)

Copyright © 2025 Vivos Inc. - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept